Transient Pneumonitis as a Possible Adverse Reaction to the BNT162b2 COVID-19 mRNA Vaccine in a Patient with Rheumatoid Arthritis: A Case Report and Review of the Literature

Table 1

Characteristics of patients with ILD after COVID-19 vaccination.

	Case
	1	2	3	4	5
Age (years)	86	65	60	66	76
Sex	M	M	M	M	F
Comorbidities	HT, DM, CKD	OMI, HL, HT	ACO, HT	None	RA, HT, myoma
Smoking	Never	Ex-smoker	Ex-smoker	NS	Never
Allergy history	NS	None	None	NS	Hay fever
Vaccine type	Pfizer-BioNTech	Pfizer-BioNTech	Pfizer-BioNTech	Pfizer-BioNTech	Pfizer-BioNTech
Dose	First	First	Second	Second	Second
Time from vaccination to symptom onset (days)	1	5	4	2	5
Symptoms	Fever, cough, dyspnea	Fever, dyspnea	Dyspnea	Fever, cough, dyspnea	Fever, cough
CRP (mg/dL)	11.4	5.5	10.9	8.7	6.4
Bilateral GGO on chest CT	Yes	Yes	Yes	Yes	Yes
Immunosuppressive therapy	Yes	Yes	Yes	Yes	No
Outcome	Survived	Survived	Survived	Survived	Survived
Reference	[7]	[8]	[9]	[10]	Current case

Note. ACO: asthma and chronic obstructive pulmonary disease overlap; CKD: chronic kidney disease; CRP: C-reactive protein; CT: computed tomography; DM: diabetes mellitus; F: female; GGO: grand glass opacity; HL: hyperlipidemia; HT: hypertension; ILD: interstitial lung disease; M: male; NS: not specified; OMI: old myocardial infarction; RA: rheumatoid arthritis.